Summary: Thermo Fisher Scientific has launched the Applied Biosystems Axiom BloodGenomiX Array and Software for precise blood genotyping in clinical research, which promises to improve the safety of blood transfusions.

Takeaways:

  1. The array detects over 40 genes and 260 antigens, including rare blood groups, tissue (HLA), and platelet (HPA) types, in a single, high-throughput assay.
  2. In a study with 14,000 DNA samples, the array showed 99.89% concordance with participants’ blood group antigen types.
  3. This technology aims to pave the way for international standards in DNA-based blood typing, enhancing the safety and efficacy of blood transfusions globally.

Thermo Fisher Scientific Inc. has introduced the Applied Biosystems Axiom BloodGenomiX Array* and Software, a solution for more precise blood genotyping in clinical research. The new array-based solution detects most extended and rare blood groups, tissue (HLA) and platelet (HPA) types in a single, high-throughput assay, supporting future advancements in donor blood matching for extended phenotypes. 

A Critical Medical Service

Blood typing is a critical medical service used to match blood and tissue types ahead of transfusions and transplants. When an individual receives incompatible blood, they can form antibodies that can increase the risk of a severe, even life-threatening, reaction to future blood transfusions. This risk increases significantly for people who receive frequent transfusions, such as patients undergoing chemotherapy and people with inherited blood disorders such as sickle cell disorder. While testing for the four main blood types (A, B, AB, and O) and determining if the blood is Rh positive or negative is common practice, there are many more blood group systems, including some extremely rare blood types. Therefore, research is critical to bring extended blood typing into strategies to mitigate potential risks of hemolytic transfusion reactions in the future. 

Further Reading: Assay Uncovers Role of Hypoxia in Red Blood Cell Aging

“Adoption of DNA-based blood typing will pave the way for large-scale genomics research and the future establishment of international standards to improve the safety and efficacy of blood transfusion for millions of patients,” says Willem H Ouwehand, PhD, FMedSci, Blood transfusion Genomics Consortium chair and Professor of Experimental Haematology at the University of Cambridge and NHS Blood and Transplant in England. 

Blood Transfusion Safety Across the Continuum

The Axiom BloodGenomiX Array covers more than 40 genes and 260 antigens across 38 blood group systems, in addition to HLA and HPA types. It was developed in collaboration with the Blood transfusion Genomics Consortium (BGC), an international partnership of blood services, research institutions and industry leaders that aims to improve the safety and efficacy of blood and platelet transfusion. In a validation study using 14,000 diverse DNA samples from the national blood services of Australia, Canada, England, Finland, the Netherlands, South Africa and the New York Blood Center, the array showed a high level of concordance (99.89%) with participants’ blood group antigen types.  

“The Blood transfusion Genomics Consortium’s goal is to develop an affordable, scalable blood typing solution that can one day be embedded in accredited labs globally,” says Connie Westhoff, SBB, PhD, BGC deputy chair and representing the National Center for Blood Group Genomics at the New York Blood Center. “Our vision is to one day make comprehensive blood typing for all donor and patient blood the standard of care.”  

For a complete workflow, the BloodGenomiX Array can be coupled with Applied Biosystems™ BloodGenomiX Reporter Software and the Applied Biosystems GeneTitan MC Instrument, helping to alleviate pain points with automated analysis, reporting and quality control. The workflow requires minimal hands-on time and can be run by existing lab staff. 

“The Axiom BloodGenomiX Array and Software provide a cost-effective, high-throughput solution for extended blood typing research,” says Kevin Lowitz, vice president and general manager, microarray solutions at Thermo Fisher Scientific. “In the future, having access to a scalable, array-based blood typing solution may help blood services effectively screen extended blood types for more precise blood matching.”  

Featured Image: The new array-based solution detects most extended and rare blood groups, tissue (HLA) and platelet (HPA) types in a single, high-throughput assay, supporting future advancements in donor blood matching for extended phenotypes. Image: Thermo Fisher.

*For research use only. Not for use in diagnostic procedures.